AstraZeneca

Named among @TIME World's Most Sustainable Companies for the third consecutive year. Sustainability is embedded in our strategy and how we operate — helping us build a more resilient, efficient business as we deliver life-changing medicines and support a healthier future for people and the planet. Learn more: learn.az/6013BDj2gd #WhatScienceCanDo

We focus on advancing research and understanding of generalised myasthenia gravis (MG), guided by those affected and aiming to improve care and outcomes. #MGAwarenessMonth #MyastheniaGravis #RareDiseases

Today we rang the opening bell at @NYSE to mark our recent share listing and harmonised trading across New York, London and Stockholm. This moment reflects the science, innovation and teamwork helping us turn bold ideas into life-changing medicines. #AZN #WhatScienceCanDo

Named one of @FinancialTimes Europe’s Climate Leaders for the 6th consecutive year. Our $1bn Ambition Zero Carbon programme has delivered: ↘️88% cut in Scope 1 & 2 emissions 🔋81% EV fleet 💡80%+ supplier spend with SBT partners. Read more: ft.com/content/1d4be2… #WhatScienceCanDo

This Eosinophilic Diseases Awareness Month, we're calling for earlier diagnosis, better care and continued progress for people living with eosinophilic diseases such as eosinophilic esophagitis (EoE). #EAM2026 #WorldEOEDay

For investor audiences and business/financial media only 📈 We delivered strong growth in Q1 2026 with Total Revenue above $15 billion, demonstrating our consistent commercial execution as we transform patient care. Learn more: astrazeneca.com/media-centre/p… #AZN #FinancialResults

Receiving a rare disease diagnosis often takes five years and involves multiple doctors, specialists, and misdiagnoses. Improving the diagnostic process can help shorten this journey for the rare disease community. #RareDisease

We highlight the neuromyelitis optica spectrum disorder (NMOSD) community and share insights to support understanding and collaboration in healthcare. #NMOAwarenessMonth #NMOSD #RareDisease

Rare Disease Day (28 Feb) is a global call to act for more than 400 million people living with rare conditions and their caregivers. Learn how we listen to and partner with the rare disease community to speed up access to diagnosis and equitable care: learn.az/6017hmwt9

More than 10,000 rare diseases affect over 400 million people worldwide. Fewer than 10% of these conditions have an approved treatment. Developing and delivering innovative therapies is essential to reach more people in need. #RareDisease

#News for #Investors and #Media📈 2025 was another year of strong growth with excellent pipeline delivery across all therapy areas and major regions. Watch our CEO Pascal Soriot share our FY 2025 results and learn more: learn.az/6013h3PrH #AZN #FinancialResults

Newborn screenings and genetic testing play a critical role in accelerating diagnosis and reducing healthcare costs, yet access remains limited. Expanding availability of these diagnostic tools can support earlier diagnosis of rare diseases. #RareDisease

#News Exciting news—we are now trading our ordinary shares on the New York Stock Exchange (NYSE) for the first time, aligning trading across the NYSE, London Stock Exchange (LSE), and Nasdaq Stockholm (STO) under a harmonised global listing structure. #AZN

While the definition of a rare disease varies across countries, the number of people affected remains significant. Improving equitable access to healthcare for those living with rare diseases is essential. #RareDisease

These awards highlight the power of innovation and collaboration. Huge thanks to our teams and partners for making this possible. #ScripAwards

We also won the 🔬 Innovation Award for the ENaBL in vivo CAR-T therapy platform with EsoBiotec.

Exciting news: AstraZeneca has been named Pharma Company of the Year at the 2025 SCRIP Awards. This recognition reflects our commitment to helping transform the future of healthcare and delivering potentially life-changing medicines to patients.

#ASH25 may be over, but the collaboration to develop new treatments for patients with blood cancers continues. Our haematology leaders share their perspectives on how scientific innovation and bold ambition are shaping future approaches to blood cancer care. #Haematology

#News We announced plans to invest $2 billion to expand our manufacturing footprint in Maryland, part of the $50 billion US commitment made in July. Supporting 2,600 jobs, strengthening US medicines supply chain, and accelerating access to transformative therapies. #AZN